The FDA Releases a Comprehensive Reaction Letter Regarding the Extended-Duration Glatiramer Acetate Form for Relapsing MS Patients.

Published Date: 14 Mar 2024

Other glatiramer acetate products were anticipated to cause more injection site reactions than GA Depot, which is made up of extended-release microspheres injected intramuscularly, usually every 28 days.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.

2.

Glioblastoma treatment breakthrough shows promise

3.

Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?

4.

Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors

5.

Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot